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Cancer of the endometrium is the most common gynecologic cancer
in the United States with 61,380 new cases and 10,920 endometrial
cancer-related deaths predicted in 2017 (American Cancer Society,
2017). Most cases are diagnosed at an early stage and low International
Federation of Gynecology and Obstetrics (FIGO) grade, allowing for a
good prognosis with surgical resection and adjuvant therapy when in-
dicated (Creasman et al., 1987).
The most common histological type of endometrial cancer is en-
dometrioid adenocarcinoma, also known as type 1 endometrial cancer.
Type 1 endometrial cancer is thought to be less aggressive, conﬁned to the
uterus at time of diagnosis, and less likely to metastasize quickly (American
Cancer Society, 2017). Conversely, uterine serous carcinoma (USC), clear
cell and FIGO grade 3 are more aggressive histologies of endometrial
cancers and more likely to metastasize (American Cancer Society, 2017).
Endometrial cancer commonly spreads via the lymphatic system, in
a stepwise fashion from the pelvic to the scalene nodes. Hematogenous
metastases, while less common, can also occur, and these most com-
monly arise in lung, liver, brain and bones (Hoﬀman et al., 2016).
Choroid metastases from gynecologic cancers, speciﬁcally endometrial
cancer, are extremely rare. We report a case of a 75 year-old female
with choroid metastases from endometrial cancer three years after
successful cytoreduction surgery.
2. Clinical scenario
In September of 2013, a 75 year-old Caucasian female underwent an
exploratory laparotomy, total abdominal hysterectomy, bilateral
salpingo-oophorectomy, pelvic lymph node dissection, and omental
biopsy. No washings were obtained. She had fourteen negative pelvic
lymph nodes and a negative omental biopsy. Given her low risk for
recurrence with a stage IA FIGO grade 2 endometrioid adenocarcinoma
conﬁned to a polyp, she did not receive adjuvant treatment and was
monitored with serial exams.
Two years after diagnosis the patient had a biopsy proven left va-
ginal sidewall recurrence. She was treated with 4500 centigray (cGy)
external beam radiation over 25 treatments, followed by high-dose
brachytherapy. She remained without evidence of disease for ﬁfteen
months until she presented to her local ophthalmologist with a one
month report of bilateral blurry vision and decreased visual acuity of
the left eye. She also endorsed “ﬂashes” in her right eye that were in-
creasing in frequency.
Metastatic cancer was suspected after initial fundoscopic exam re-
vealed two darkened, raised areas in the choroid of the left eye in
December of 2016 (Fig. 1). Visual acuity was 20/25 vision in her right
eye and 20/300 in her left eye. Slit lamp exam demonstrated ﬁndings of
a normal anterior chamber bilaterally with notable mild nuclear cat-
aract changes occurring bilaterally. Dilated fundus exam revealed
choroidal lesions elevating the retina in both eyes. Two choroidal le-
sions were noted along the superior arcade in the macula of the left eye,
and the right eye had evidence of two choroidal lessons inferonasally.
Masses were conﬁrmed and characterized with ultrasound. Whole body
positron emission tomography (PET) showed diﬀuse metastatic disease
throughout the bones, lungs, mediastinal and subclavicular lymph
nodes, left globe, and left shoulder subcutaneous nodule. Ultrasound
guided ﬁne needle aspiration biopsy of the supraclavicular node re-
sulted as metastatic poorly diﬀerentiated carcinoma harboring high
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grade features (Fig. 2). On second opinion pathology review of her
hysterectomy specimen demonstrated high grade endometrial adeno-
carcinoma with endometrioid and serous features with no lymphovas-
cular space nor myometrial invasion (Fig. 3).
She completed ﬁve of six planned cycles of intravenous carboplatin
and dose-dense paclitaxel in May of 2017; the ﬁnal cycle was held
secondary to neuropathy. A complete response was seen on PET scan
one month post-treatment; however, two months later, follow-up oph-
thalmologic examination revealed decreased visual acuity in the left
eye, diminished to the point of only being able to count ﬁngers placed
three feet from the patient. Fundoscopic exam and ultrasound testing
demonstrated enlargement of macular choroidal lesions in the left eye.
After presenting to her medical oncologist with persistent nausea and
vomiting three months following completion of chemotherapy, a brain
magnetic resonance imaging (MRI) showed multiple brain metastases,
including within the left choroid (Fig. 4). The patient began whole
brain radiation and completed 1000 cGy of the prescribed 3000 cGy.
Due to declining health, the patient elected for hospice and died in
September of 2017.
Fig. 1. Choroid lesion (solid arrow) seen on funduscopic exam of patient's left eye.
Fig. 2. Hematoxylin and eosin stain of supraclavicular lymph node with metastatic poorly diﬀerentiated carcinoma harboring high grade features (A). The tumor cells demonstrate diﬀuse
positivity for cytokeratin (B), PAX-8 (C) and p16 (D) with no expression of p53 (E) and ER (F) (Original magniﬁcation ×200 [A–F]).
Fig. 3. High-grade endometrial adenocarcinoma with endometrioid and serous features (A & B). Ancillary studies demonstrate diﬀuse positivity for p16 (C), and minimal expression of
vimentin (D) with lack of p53 immunoreactivity (E), and estrogen receptor expression (F). {Original magniﬁcation ×100 [A]; original magniﬁcation ×200 [B–F]; hematoxylin and eosin
(A&B)}. Area shown by white asterisk represents carcinoma with endometrioid features and the area shown by black asterisk represents carcinoma with serous features.
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3. Discussion
Generally, stage IA endometrioid adenocarcinoma has a good
prognosis with an overall ﬁve-year survival of 88% (National Cancer
Institute, 2017). Surgical management is the deﬁnitive treatment of
choice. Recurrence most commonly occurs in the vagina and salvage
rates with radiation are high (Nag et al., 2002). In contrast, stage I USC
has a ﬁve-year survival of 79.9% (Binder and Mutch, 2014), and the
recurrence rates are much higher at 50–90%, with the majority being
extrapelvic (El-Sahwi et al., 2012).
To our knowledge, only 3 cases of choroid metastases from en-
dometrial cancer have been described in the literature (Cormio et al.,
2006; Lawrence et al., 2010; Saxena et al., 2012). Lawrence, et al. de-
scribed a 70 year-old patient with stage IVB USC who presented four
years after surgery and adjuvant chemoradiation with sudden onset of
severe pain and vision loss in her right eye, requiring enucleation. Six
months prior to presentation, the patient had received additional pal-
liative chemotherapy for pulmonary metastases (Lawrence et al., 2010).
Saxena et al. reported a 56 year-old patient with stage IV endometrioid
adenocarcinoma who presented one year after surgery and adjuvant
radiation with a one month history of gradual and painless decrease in
vision of her right eye, and died within one month of presentation
(Saxena et al., 2012). Cormio et al. reported a case in which a 31 year-
old patient with suspected early stage endometrial cancer received
fertility-sparing megestrol acetate for 6 months with serial clinical
exams thereafter. Two years after initial treatment she recurred and
underwent a total abdominal hysterectomy, bilateral salpingo-oophor-
ectomy and lymph node sampling, revealing stage IA grade 1 en-
dometrioid adenocarcinoma, requiring no adjuvant therapy. This pa-
tient was disease-free for three years, until she had multi-focal
recurrence noted in her lungs, pelvis and left eye. She was treated with
intravenous carboplatin and paclitaxel every three weeks, with minimal
response in the choroid lesion, although response was seen in her lung
metastases. After completing six cycles of chemotherapy, MRI con-
ﬁrmed left choroid and multiple metastatic brain lesions. The patient
declined further treatment and died within one month (Cormio et al.,
2006).
While extremely rare, metastatic disease to the eye should not be
overlooked in a patient with a history of endometrial cancer and new
onset vision changes. Posterior ciliary arteries, a large component of the
high ﬂow choroidal vasculature, are thought to aid in the hemato-
genous dissemination of tumor emboli from distant primary tumors
(Cormio et al., 2006; Shields et al., 1997). As seen in our patient, the
most common symptoms at time of presentation are blurry vision, de-
creased visual acuity, ﬂashers and ﬂoaters, and pain; however, some
patients may have no symptoms. Vision complaints in patients with a
history of any gynecologic cancer warrant timely evaluation, including
funduscopic examination to rule out metastatic lesions. Currently the
American Academy of Ophthalmology recommends all adults receive a
comprehensive eye evaluation at age 40 (American Academy of
Ophthalmology, 2015). Given the average age at time of diagnosis of
endometrial cancer is 60 (American Cancer Society, 2017), patients
should have a routine baseline eye exam established upon diagnosis.
Furthermore, it is important to ensure endometrial cancer patients with
new vision symptoms have a comprehensive eye exam to assess for
possible metastatic disease. Upon the diagnosis of uveal metastatic
disease, patients should undergo contrast-enhanced MRI which is more
sensitive than computed tomography or FDG-PET scan to detect brain
metastases (Fink and Fink, 2013). Treatment is dependent upon the
primary tumor with external beam radiation or primary site-speciﬁc
systemic chemotherapy being the two most common treatment mod-
alities.
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